Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types
Over the past decade, immune checkpoint inhibitor (ICI) therapies have redefined the standard of care in many cancer types across stages and indications. Backed by large randomised controlled trials (RCTs) across several tumour types, perioperative ICI therapies have become an important addition to our treatment options. However, questions regarding the importance of subsequent treatment administered to trial patients in the control group (often placebo or surveillance) after recurrence quickly arose, leading to debates over trial design and application in real-world practice.
